Roche Signs US$2.8 B Deal with Alnylam to Develop RNAi Therapeutic for Hypertension

By Amit Kaushik

Pharma Deals Review: Vol 2023 Issue 8 (Table of Contents)

Published: 2 Aug-2023

DOI: 10.3833/pdr.v2023.i8.2798     ISSN: 1756-7874

Section: Research & Development



In a groundbreaking move with the potential to revolutionise the treatment of cardiovascular diseases, Roche has entered into a licensing agreement with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details